Mirtazapine in Alzheimer-associated Weight Loss
Weight loss is a frequent problem associated with Alzheimers disease (AD). Mirtazapine has weight loss as a frequent side effect.
The aim of this retrospective study is to check whether mirtazapine 30 mg (once daily) can counteract weight loss in patients with AD or mixed dementia (AD + vascular).
|Study Design:||Observational Model: Case-Only
Time Perspective: Retrospective
|Official Title:||Mirtazapine in Alzheimer-associated Weight Loss: a Retrospective Phase IV Study|
- body weight [ Time Frame: 6 months ] [ Designated as safety issue: No ]
|Study Start Date:||January 2004|
|Study Completion Date:||December 2011|
|Primary Completion Date:||November 2011 (Final data collection date for primary outcome measure)|
Please refer to this study by its ClinicalTrials.gov identifier: NCT01505504
|Brussels, Belgium, 1020|